X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://endpts.com/reata-culls-bardoxolone-ending-decade-of-rd-on-troubled-kidney-disease-drug/
https://www.fiercebiotech.com/biotech/reata-kyowa-kirin-partnered-med-bardoxolone-faces-music-after-ph-3-flop-ending-13-year-saga
https://seekingalpha.com/news/3806235-reta-stock-slips-as-fda-rejects-kidney-disease-drug
https://endpts.com/fda-slams-reatas-kidney-drug-as-ineffective-ahead-of-adcomm-meeting-wednesday/
https://www.globenewswire.com/fr/news-release/2021/03/01/2184047/0/en/Reata-Pharmaceuticals-Inc-Submits-NDA-for-Company-s-Lead-Program-Bardoxolone-in-Alport-Syndrome.html#:~:text=(Nasdaq%3A%20RETA)%20(%E2%80%9C,U.S.%20Food%20and%20Drug%20Administration
https://www.pharmacompass.com/pdf/news/reata-announces-ve-results-from-2y-of-the-pivotal-ph3-study-of-bardoxolone-1607402080.pdf
https://www.globenewswire.com/news-release/2020/07/28/2068482/0/en/Reata-Announces-Initiation-of-Investigator-Sponsored-Study-Evaluating-Bardoxolone-for-Complications-Associated-with-COVID-19.html
https://endpts.com/two-preclinical-biotechs-riding-the-ipo-wave-this-week-look-to-raise-466m-plus-blackstones-galakatos-backs-reata-to-the-tune-of-350m/
https://endpts.com/reatas-bardoxolone-offers-promise-in-patients-with-rare-kidney-disorder/
https://www.fiercebiotech.com/biotech/reata-s-kidney-med-bardoxolone-delivers-phase-3-teeing-up-fda-filing
https://www.fiercebiotech.com/biotech/reata-s-bardoxolone-hits-goals-phase-2-kidney-disease-trial
https://alportsyndromenews.com/2018/07/30/phase-2-alport-trial-shows-bardoxolone-may-reverse-kidney-damage/
https://reatapharma.gcs-web.com/news-releases/news-release-details/reata-announces-positive-phase-2-data-bardoxolone-methyl-ckd
https://reatapharma.gcs-web.com/news-releases/news-release-details/reata-announces-kyowa-hakko-kirin-initiated-ayame-phase-3-trial
https://reatapharma.gcs-web.com/news-releases/news-release-details/reata-announces-orphan-drug-designation-european-commission
https://reatapharma.gcs-web.com/news-releases/news-release-details/bardoxolone-methyl-improved-kidney-function-patients-autosomal
https://reatapharma.gcs-web.com/news-releases/news-release-details/reata-provides-update-phase-2-portion-cardinal-study-bardoxolone
https://reatapharma.gcs-web.com/news-releases/news-release-details/reata-announces-improvements-kidney-function-bardoxolone-methyl
https://reatapharma.gcs-web.com/news-releases/news-release-details/reata-announces-publication-efficacy-data-beacon-study
Market Place
Share 
